-
Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Prolia
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving market approval from the National Medical Products Administration (NMPA) for its biosimilar version of US major Amgen’s Prolia (denosumab). This development marks Mabwell’s drug as the world’s second biosimilar of Prolia, which is used to treat osteoporosis in postmenopausal…
-
Roche’s Cosentyx 300mg Dosage Approved by NMPA for Ankylosing Spondylitis Treatment
•
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the National Medical Products Administration (NMPA) has approved the 300mg dosage regimen of Cosentyx (secukinumab) for use in treating ankylosing spondylitis (AS). This approval represents a significant advancement in the management of this chronic inflammatory disease. Approval Based on MEASURE 3…
-
Changzhou Qianhong Bio-pharma Receives NMPA Approval for QHRD107 Phase II AML Study
•
China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced obtaining approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its Category 1 drug QHRD107 in acute myeloid leukemia (AML). The drug is being developed for use in combination with venetoclax and/or azacitidine,…
-
Konruns Pharmaceutical Reports Positive Efficacy Results for KC1036 in Advanced ESCC
•
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the publication of efficacy study results for its Category 1 chemical drug, KC1036, in the treatment of advanced esophageal squamous cell carcinoma (ESCC). The drug was evaluated as a second-line therapy for patients who have already failed previous standard treatments. Study…
-
Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation
•
The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership with the Eye Valley in Wenzhou. This collaboration aims to promote the transformation of significant scientific and technological achievements in ophthalmology, attract high-level talent for innovation and entrepreneurship, and support the development of high-quality pharmaceutical…
-
Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis
•
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a Phase III clinical study for its allogeneic human adipose mesenchymal progenitor cell injection, AlloJoin. This follows a successful randomized, double-blind, controlled multi-center Phase II clinical study, which included a 96-week follow-up and preliminarily demonstrated a…
-
Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan drug designation (ODD) status from the US Food and Drug Administration (FDA) for its next-generation FGFR4 mutant inhibitor, ABSK012, intended for the treatment of soft-tissue sarcoma. Preclinical Efficacy of ABSK012 Against FGFR4 MutantsPreclinical studies have…
-
Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization
•
China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached RMB 3.214 billion (USD 466.5 million), representing a remarkable increase of 91.1% year-on-year (YOY). This growth was driven by the successive commercialization of various products, with the company currently having launched five products in China…
-
Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates
•
China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key business updates. The company reported revenues of RMB 12.8 million (USD 1.86 million) for the year ending 31 December 2022, an increase of RMB 12.7 million (USD 1.84 million) compared to the previous year, primarily…
-
ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has entered into a strategic partnership with Wuhan Banbiantian Medical Technology Development Co., Ltd. The collaboration, which is centered around digitalization technologies, is designed to capitalize on the “medicine, device, drug” linkage model. While financial specifics…
-
Pharmaron Secures UK Government Grant to Expand Viral Vector Manufacturing Facility
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced the receipt of a substantial grant from the UK government’s Life Sciences Innovation Manufacturing Fund (LSMIF). The grant will facilitate the expansion of Pharmaron’s existing viral vector and DNA manufacturing facility in Liverpool,…
-
HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC
•
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor of VEGFR-1, -2, and -3, fruquintinib. The drug is proposed for the treatment of refractory metastatic…
-
Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’
•
Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., This strategic move allows Apollomics’ A shares and warrants to be traded on the NASDAQ under the ticker symbols “APLM” and “APLMW” respectively. The merger, which…
-
Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
•
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its biosimilar version of Novo Nordisk’s Victoza (liraglutide). This new biosimilar is intended for use in treating patients with type 2 diabetes. Liraglutide…
-
Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership
•
Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide drug candidate, as part of an ongoing licensing deal with US-based RayzeBio. The agreement aims to develop and commercialize the product in Greater China, expanding Ablaze’s portfolio and strengthening its commitment to cancer therapies. Licensing…
-
Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study of its novel small molecule chemical drug, FCN-159. The study will evaluate the drug’s efficacy as a treatment…
-
Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company, has announced the start of a Phase III clinical study in the Chinese mainland for its HER2-targeted antibody drug conjugate (ADC), FS-1502. The study is focused on the treatment of HER2-positive unresectable, locally advanced, or…
-
Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered into a strategic partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) and Indonesian pharmaceutical company Combiphar. The collaboration aims to strengthen the cooperation between China and Indonesia in the vaccine sector. Under the terms of the…
-
CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment
•
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology (JCO) has published the results of the registrational clinical study GEMSTONE-201 for the PD-L1 antibody sugemalimab in the treatment of relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). This study represents the largest registrational clinical…
-
IceCure Medical Gains NMPA Approval for Cryoablation Technology in China
•
Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s National Medical Product Administration (NMPA) for the commercial launch of its IceSense3 disposable cryoprobes product and its accompanying product console. This minimally-invasive cryoablation technology utilizes liquid nitrogen to freeze and destroy tumors, offering a treatment…
